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Objectives: To evaluate changes in demographics, incidence, prevalence, treatment modal-
ities, and survival of COPD patients on long-term oxygen therapy (LTOT) from year 2001
e2010 in Denmark.
Methods: All 14,965 COPD patients with COPD treated LTOT in Denmark in the period 2001
e2010.
Results: During the study period, the incidence and prevalence of COPD patients on LTOT
increased from 30.5 to 32.2 per 100.000, and from 42.0 to 48.1 per 100.000, respectively. Mean
age of patients increased from 73.4 to 74.8 years, P < 0.001. An increasing number of patients
were prescribed LTOT in connection with discharge after hospitalisation for an exacerbation
(2001 vs. 2010: 76.5% vs. 91.7%, P < 0.001); were prescribed oxygen 15e24 h/day (85.8% vs.
89.5%, P < 0.001); had mobile oxygen (56.4% vs. 94.2%, P < 0.001), and stopped LTOT alive
within 6 months (20.6% vs. 30.8%, P < 0.001). Ninety-nine percent of the patients received ox-
ygen concentrator or liquid oxygen with no change in the study period (P Z 0.66).
The median survival on LTOT increased insignificantly from 16.5 to 17.8 months (PZ 0.12).
Women had a lower risk of dying compared with men, with an adjusted hazard ratio of 0.81
(95% confidence interval (CI) 0.78e0.84), P < 0.001). During the study period, the risk of death
for women, compared to men, decreased significantly with a hazard ratio of 0.978 (95% CI:
0.964e0.992) per calendar year.
Conclusions: The incidence of COPD patients on LTOT in Denmark has levelled of during recent
years, and the quality of prescribing LTOT and follow up has improved. Women had better sur-
vival than men, and this difference has increased during the study period.
ª 2013 Elsevier Ltd. All rights reserved.2 B, DK-3140 Aalsgaarde, Denmark. Tel.: þ45 21969087.
et.dk, Thomasringbaek@gmail.com (T.J. Ringbaek).
3 Elsevier Ltd. All rights reserved.
3.10.025
512 T.J. Ringbaek, P. LangeTwo randomised studies in the early 80’ties showed that
long-term oxygen therapy (LTOT) under certain circum-
stances improved survival in hypoxaemic patients with
COPD [1,2]. Since then, LTOT has been widely accepted,
and the incidence and prevalence have increased steadily
[3e5]. Previous studies have shown that adherence to
criteria for LTOT was poor e especially when non-
pulmonary specialists including general practitioners were
responsible for the treatment [6e9]. Studies on survival of
COPD patients on LTOT have reported median survival that
varies between approximately 2 years [10,11] and 4 years
[2,12]. Information on treatment modalities, adherence to
guidelines for LTOT, incidence, prevalence, and mortality
stem primarily from older or small studies [3,4,7,13].
In this study of all Danes on LTOT during the first decade
of the 21st century, we aimed to evaluate the most recent
trends in treatment modalities, incidence, prevalence, and
mortality of COPD patients on LTOT.
Methods
Collection of information
The Danish Oxygen Register covers more than 99% of the
Danish population, which comprises about 5.4 million in-
habitants [4]. In the period from 01.01.2001 to 31.12.2010,
16,250 treatment episodes in 14,965 different COPD pa-
tients have been registered. The oxygen suppliers provide
information on patients on home oxygen therapy, their
prescriptions, and possible termination of therapy. The
National Health Services Central Register provided infor-
mation on diagnosis for LTOT and on vital status up to 31
December 2011. Following coding according to ICD 10 was
used to diagnose COPD when LTOTwas initiated: either J41-
J44 as the primary diagnosis or J96 as the primary diagnosis
combined with J41-J44 as the secondary diagnosis. In gen-
eral, the diagnosis of COPD in Denmark has high validity
[14]. Survival rates were calculated in 14,535 patients who
started LTOT for the first time in the study period. The
mean observation time of this group of patients was 6.0
years (1.0e11.0 years). The regional Ethical Committees
and the Data Inspection Board have approved the study.
Guidelines and organization of home oxygen
therapy in Denmark
The recommended guidelines for prescribing domiciliary
oxygen in Denmark are in line with European guidelines and
have not been changed during the study period [15]. In
general, only specialists in internal medicine or respiratory
medicine can prescribe LTOT. GPs are advised not to pre-
scribe LTOT, but to referrer potential patients to the local
hospital. The prescribing doctor can choose between large
gas cylinders, liquid oxygen or a concentrator alone or
combined with small portable gas cylinders. In cases of a
large consumption of oxygen, the suppliers will recommend
concentrator or liquid oxygen on economic grounds. Liquid
oxygen became available in July 1995. It is recommended
for the most mobile patients. Due to high weight, liquid
oxygen can’t be delivered to patients living in blocks of
flats without a lift. In general, the price per day for liquidoxygen is double that of a concentrator, and the price for a
concentrator combined with small gas cylinders is in be-
tween. All costs of oxygen treatment, including consump-
tion of electricity by oxygen concentrators, are covered by
the local hospital.
Statistical analyses
Kaplan Maier test was employed to compare cumulative
proportion of mortality. Cox regression model was used to
determine whether the year of start of LTOT and gender
were individual predictors of survival, and whether there
was an interaction between calendar year and gender. The
covariates in the multivariate models were age and pre-
scribed oxygen 15e24 h per day. The results of regression
analyses are given in terms of estimated relative risks
(hazard ratios) with corresponding 95% confidence intervals
(CIs). The chi-squared and two sample t-tests were used as
appropriate to compare differences between groups. Lo-
gistic and linear regression analyses were used to test for
trends with calendar year as categorical variable. A two-
sided p-value of <0.05 was considered significant. Ana-
lyses were performed with the statistical package for the
social sciences (SPSS) ver. 13.0 (SPSS Inc., Chicago, USA).
Results
Incidence and prevalence of COPD patients on
LTOT
On the 31st of December 2001, a total of 2247 COPD pa-
tients (42.0 per 100,000 inhabitants) received LTOT (Fig. 1).
During the following 9 years, the number of patients on
LTOT has increased constantly to reach a prevalence of
48.1 per 100,000 in 2010. Correspondingly, the incidence of
oxygen therapy increased insignificantly from 30.5 to 32.2
per 100,000 (Fig. 1).
Patients’ characteristics and treatment modalities
The majority of COPD patients were women and older than
70 years of age (Table 1, Fig. 2). During the study period, the
mean age of patients who started LTOT in the study period
increased from 73.4 (SD Z 9.0) years to 74.8 (9.7) years,
p < 0.001 (Table 2). Most of the COPD patients were pre-
scribed oxygen therapy by a hospital doctor immediately
after an acute hospitalization, and the number of pre-
scriptions from general practitioners was continuously
declining towards zero during the study period. An increasing
number of the COPD patients were prescribed oxygen at
least 15 h daily and had delivered oxygen concentrator and
mobile oxygen, whereas, in general, the oxygen flow
remained low (1.5 L/minute) (Table 2, Fig. 2).
Small, but statistically significant, differences were seen
between men and women (Table 1). Compared to men,
women started LTOT more often in connection with hospi-
talization and more often stopped LTOT within the first six
months. Women were prescribed a lower oxygen flow than
men and the treatment was more often specified to take
place for 15e24 h per day.
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Figure 1 Changes in the incidence and prevalence (number per 100.000) of long-term oxygen therapy in COPD from year
2001e2010.
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Through the study period, 9377 (64.5%) deaths were
observed, and the median survival for the patients
increased insignificantly from 16.5 to 17.8 months
(p Z 0.12) (Table 1). The median survival increased from
17.9 to 21.6 months in women (p Z 0.029), but decreased
from 15.5 to 14.0 months in men (p Z 0.61). Patients who
started LTOT in the outpatient clinic had a better survival
than patients who started LTOT in connection with a hos-
pital admission (median survival 22.6 months versus 17.1
months; P < 0.001).
Females had a lower risk of death compared with males,
with a hazard ratio of 0.81 (95% confidence interval (CI)
0.78e0.84), p < 0.001), using Cox proportional hazard
regression adjusted for age and prescribed oxygen for
15e24 h per day. During the study period, the risk of death
for women compared to men decreased significantly with a
hazard ratio of 0.978 (95% CI: 0.964e0.992) per calendar
year (Fig. 3).Table 1 Patients’ characteristics, treatment modalities, and su
the study period.
All patients
Number of patients (%) 14,535
Age, years, mean (SD) 74.1 (9.2)
Started LTOT within one week after
discharge from hospital, %
85.2
Prescribed LTOT by a general practitioner, % 2.4
Prescribed oxygen at least 15 h/day, % 89.9
Oxygen concentrator or liquid oxygen, % 93.0
Liquid oxygen, % 5.5
Mobile oxygen, % 66.1
Oxygen flow, L/minute, mean (SD) 1.48 (0.8)
Stopped LTOT alive within 6 months,a % 25.5
Survival, months, median (95%-CI) 18.0 (17.4e18.6)
CI: Confidence interval.
a Among patients who were alive at least six months.Discussion
This study evaluates temporal trends in LTOT for COPD in
Denmark during the period 2001 to 2010. We describe
incidence, prevalence, patient characteristics, treatment
modalities, adherence to criteria for correctly prescribed
oxygen, and survival in all Danish COPD patients on LTOT.
The increase in the annual incidence of LTOT in COPD pa-
tients has levelled off during the study period. From 1995 to
2001 the incidence increased from 20.5 to 30.5 per 100.000,
thereafter only to increase insignificantly to 32.2 per
100.000 the following nine years [4]. An increasing number
of clinically unstable COPD patients who had oxygen ther-
apy prescribed immediately after a hospitalisation may
explain some of the increase in the incidence. Slightly
improved survival could also have contributed to the in-
crease in prevalence.
In general, data on prevalence of home oxygen therapy
outside Denmark are either old or based on regional in-
ventories. According to The French Oxygen Register, thervival in COPD patients who started LTOT for the first time in
Males Females P-value for difference
between males and
females
5836 (40.2) 8699 (59.8) NA
74.3 (9.3) 74.0 (9.2) 0.10
83.2 86.4 <0.001
3.1 1.9 <0.001
88.3 91.0 <0.001
92.7 93.2 0.23
5.7 5.3 0.34
65.8 66.2 0.67
1.56 (0.9) 1.42 (0.7) <0.001
22.4 27.5 <0.001
15.0 (14.3e15.8) 20.4 (19.5e21.2) <0.001
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Figure 2 Trends in patients’ characteristics and treatment modalities in COPD patients who started long-term oxygen therapy
during 2001e2010.
514 T.J. Ringbaek, P. Langeprevalence of COPD patients on LTOT in France was about 28
per 100.000 in 1992 [16], and The Swedish Oxygen Register
reportedan incidenceof approximately 7.4per 100.000 anda
prevalence of 24 per 100.000 in 2000 [3]. When LTOT is pre-
scribed to clinically unstable patients, about 30e50% of the
patients don’t fulfil the hypoxaemia criteria at re-evaluation
at 2e3 months [2,17]. Therefore, reassessment is recom-
mended after 1e3 months treatment [15]. Accordingly, we
found that an increasing number of patients stopped LTOT
shortly after starting this treatment, indicating that blood
gases had improved, and that LTOT was no longer needed.
Supporting an improving quality of LTOT in Denmark, we also
found an increasing number of patients with correctly pre-
scribed oxygen (15e24 h per day).Table 2 Patients’ characteristics, treatment modalities, and s
who started LTOT 2001 and 2010.
Started 2001
Number of patients (%) 1632
Females, % 59.5
Age, years, mean (SD) 73.4 (9.0)
Started LTOT within one week after
discharge from hospital, %
76.5
Prescribed LTOT by a general practitioner, % 3.9
Prescribed oxygen at least 15 h/day, % 85.8
Oxygen concentrator or liquid oxygen, % 98.8
Liquid oxygen, % 4.6
Mobile oxygen, % 56.4
Oxygen flow, L/minute, mean (SD) 1.40 (0.7)
Stopped LTOT alive within 6 monthsa, % 20.6
Survival, months, median (95%-CI) 16.5 (14.8e18.2)
CI: Confidence interval.
a Among patients who were alive at least six months.
b Chi2-test used to compare incidences.
c Log Rang test.
d Logistic regression, linear regression, and Cox regression models (We observed that an increasing proportion of our pa-
tients had access to mobile oxygen devices. There could be
at least three explanations for this change. More patients
could have been supplied with small cylinders as back up
for an oxygen concentrator, or the doctors have become
more liberal in prescribing mobile oxygen, and finally, pa-
tients could actually be more mobile and need portable
oxygen regularly. However, increasing age of patients on
LTOT and no significant improvement in survival do not
support the notion of increased mobility among the
patients.
A minority of our patients had liquid oxygen, and this has
not changed over time. Similarly, only 2e3% of Swedish
patients on LTOT have liquid oxygen [13].urvival in COPD patients on LTOT: changes between patients
Started 2010 P-level for
difference
between
2001 and 2010
P-level for trend
in the period
2001 to 2010d
1779 0.13b
60.1 0.72 B Z 0.01; P Z 0.06
74.8 (9.7) <0.001 B Z 0.21; P < 0.001
91.7 <0.001 B Z 0.11; P < 0.001
0.3 <0.001 B Z 0.18; P < 0.001
89.5 0.001 B Z 0.09; P < 0.001
99.0 0.66 B Z 0.01; P Z 0.38
3.6 0.14 B Z 0.03; P Z 0.005
94.2 <0.001 B Z 0.11; P < 0.001
1.50 (0.8) <0.001 B Z 0.01; P < 0.001
30.8 <0.001 B Z 0.05; P < 0.001
17.8 (15.8e19.8) 0.18c Hazard ratio 1.00
(0.99e1.01); P Z 0.40
per calendar years).
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Figure 3 Median survivals in patients with COPD receiving LTOT according to year of entrance for males and females,
respectively.
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ister, we found that the age of the patients on LTOT and the
prescribed oxygen flow are increasing [18]. The increasing
age of patients and the slightly higher incidence of COPD
patients on LTOT may be explained by a “wave” of birth
cohorts with high prevalence of COPD rolling over Denmark,
which has been suggested by previous Danish studies
[19,20].
Although the prescribed oxygen flow is increasing, it’s
still significantly lower than in the randomised clinical tri-
als, where flows in the range 1.5e2.5 L/minute were used
[1,2].
In contrast to most other countries, more females than
males are on LTOT in Denmark and Sweden [13]. We
observed small but statistically significant differences be-
tween women and men on LTOT: Women started more
often LTOT immediately after hospitalisation and stopped
more often LTOT within 6 months. They were more often
prescribed oxygen at least 15 h per day and a lower flow of
oxygen. Finally, women had better survival, and this dif-
ference increased significantly during the study period.
Co-morbidities are common in COPD patients on LTOT e
especially cardiovascular diseases, which contribute to the
high mortality seen in these patients [21]. A Spanish study
compared two cohorts of COPD patients after hospital
discharge from 1996 to 7 and 2003e4, and found improved
long-term survival rates, even after adjusting for covariates
[22]. The authors suggested that better management and
treatmentofCOPDandco-morbiditieswas responsible for the
better prognosis. In our study period, better treatment of
COPD hospitalised patients has also been documented in
Denmark [19]. In addition, we had expected survival of our
LTOT patients to improve during the study period due to
better treatment of cardiovascular co-morbidities. However,
we showed that better survival over timewasonly observed in
females, and to our knowledge this trend in gender related
survival among COPD patients has not previously been
demonstrated. Another explanation for better survival in fe-
males in the study period may be the tendency of starting
LTOT in women with less severe COPD or less co-morbidity.
Unfortunately, we have no information on co-morbidities,
lung function, smoking status, blood gases, actual use ofoxygen,andmedical treatmentofCOPDandco-morbidities to
evaluate potential changes over time in males and females.
Although survival of our COPD patients has improved
slightly, it is still substantially lower than in other coun-
tries. The median survival of our patients was 17.8 months
compared to 24e36 months in other studies [10e13]. Most
of our patients started LTOT in an unstable clinical condi-
tion right after a hospital admission, which was related to
high mortality. In contrast, only 18% of the Swedish COPD
patients initiated LTOT during an exacerbation [3]. We
believe that different practice in initiating LTOT (stable or
unstable condition) may at least partly explain the higher
mortality in our patients compared to patients in the other
studies.
In conclusions, the incidence of COPD patients on LTOT
in Denmark has levelled of during recent years and the
quality of the prescription of LTOT and of the follow up of
has improved. Women had better survival than men, and
this difference has increased during the study period.
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